Abstract
The renin-angiotensin system hormone angiotensin II (Ang II) plays a central role in the pathophysiology of vasoconstriction, cardiovascular hypertrophy and hyperplasia. Two distinct subtypes of Ang II receptor, type 1 (AT1) and type 2 (AT2), have been identified, and both have been shown to belong to the G protein-coupled receptors (GPCRs) superfamily. AT1 and AT2 receptors may have antagonistic action. While the crystal structures of GPCRs obtained from the rhodopsin, opsin, and ß1 and ß2- adrenergic receptors have recently been described in different conformational states, the crystal structures of Ang II receptors have not been elucidated. The conformation range and dynamics of the effects of ligands on GPCRs may differ from one receptor to another. This review focuses on the structure and function of Ang II receptors, such as the movement of transmembrane helices, functional selectivity for AT1 receptor activation, the possibility of constitutive activity of wild-type Ang II receptors and the homo- and hetero-dimerization of Ang II receptors.
Keywords: Angiotensin II receptors, G protein-coupled receptor, structure and function.
Current Pharmaceutical Design
Title:Recent Progress in Molecular Mechanisms of Angiotensin II Type 1 and 2 Receptors
Volume: 19 Issue: 17
Author(s): Shin-ichiro Miura, Satoshi Imaizumi and Keijiro Saku
Affiliation:
Keywords: Angiotensin II receptors, G protein-coupled receptor, structure and function.
Abstract: The renin-angiotensin system hormone angiotensin II (Ang II) plays a central role in the pathophysiology of vasoconstriction, cardiovascular hypertrophy and hyperplasia. Two distinct subtypes of Ang II receptor, type 1 (AT1) and type 2 (AT2), have been identified, and both have been shown to belong to the G protein-coupled receptors (GPCRs) superfamily. AT1 and AT2 receptors may have antagonistic action. While the crystal structures of GPCRs obtained from the rhodopsin, opsin, and ß1 and ß2- adrenergic receptors have recently been described in different conformational states, the crystal structures of Ang II receptors have not been elucidated. The conformation range and dynamics of the effects of ligands on GPCRs may differ from one receptor to another. This review focuses on the structure and function of Ang II receptors, such as the movement of transmembrane helices, functional selectivity for AT1 receptor activation, the possibility of constitutive activity of wild-type Ang II receptors and the homo- and hetero-dimerization of Ang II receptors.
Export Options
About this article
Cite this article as:
Miura Shin-ichiro, Imaizumi Satoshi and Saku Keijiro, Recent Progress in Molecular Mechanisms of Angiotensin II Type 1 and 2 Receptors, Current Pharmaceutical Design 2013; 19 (17) . https://dx.doi.org/10.2174/1381612811319170002
DOI https://dx.doi.org/10.2174/1381612811319170002 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting DNA Minor Groove by Hybrid Molecules as Anticancer Agents
Current Medicinal Chemistry Phosphoproteomics: Challenges and Opportunities
Current Proteomics The Smart Targeting of Nanoparticles
Current Pharmaceutical Design Studies on Structures and Functions of Kinases leading to Prostate Cancer and Their Inhibitors
Current Enzyme Inhibition Acridine Orange is an Effective Anti-Cancer Drug that Affects Mitochondrial Function in Osteosarcoma Cells
Current Pharmaceutical Design HIV and Respiratory Disease: A Contemporary Perspective
Current Respiratory Medicine Reviews Paraneoplastic Pemphigus: Autoimmune-Cancer Nexus in the Skin
Anti-Cancer Agents in Medicinal Chemistry Drug Targeting Systems for Cancer Therapy: Nanotechnological Approach
Mini-Reviews in Medicinal Chemistry Nanocarriers for Photodynamic Therapy Intended to Cutaneous Tumors
Current Drug Targets Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib
Current Cancer Drug Targets MicroRNAs in Cancer Therapy: From Bench to Bedside
Current Cancer Therapy Reviews FDG-PET/CT and SPECT/CT in Oncology
Current Medical Imaging Selective Activation of Intracellular Signalling Pathways in Dendritic Cells for Cancer Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry Preclinical Development of Novel Anti-Glioma Drugs Targeting the Endoplasmic Reticulum Stress Response
Current Pharmaceutical Design Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets The Interactions of Anticancer Agents with Tea Catechins: Current Evidence from Preclinical Studies
Anti-Cancer Agents in Medicinal Chemistry 2-Methoxyestradiol as a Potential Cytostatic Drug in Gliomas?
Anti-Cancer Agents in Medicinal Chemistry Novel Drug Delivery Systems for Sustained and Targeted Delivery of Anti-Cancer Drugs: Current Status and Future Prospects
Current Drug Delivery In Silico Studies in Drug Research Against Neurodegenerative Diseases
Current Neuropharmacology The Wnt Pathway: Emerging Anticancer Strategies
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)